A group of consumer, senior, patient safety organizations and small insurers, including Community Catalyst and various state public interest research groups, filed their own comments with the FDA o
A group of consumer, senior, patient safety organizations and small insurers, including Community Catalyst and various state public interest research groups, filed their own comments with the FDA on fair balance. Will pharma listen ?
Consumers want to have their own say in fair balance on prescription drug ads. Among their recommendations ;
This is exactly what I have been hearing in two years of qual and quant research and I believe that these requests are reasonable. One other requirement that I believe is necessary is that drug websites have a "roll-over" definition pop-up for complicated medical terms so that consumers can understand label language. It seems that most drug companies do not want to hire writers to take complicated medical language and turn it into easy to understand language that consumers can actually understand and the FDA issues a letter recently to a company that "simplified" it's label language.
PhRMA should be acting as a bridge between consumer groups and pharma marketers to start down the road to earning trust and doing what consumers want and need not doing what is just best for marketers.
Often criticised for not properly adopting new web technologies, pharma proves it knows a thing or two about the corporate website.
Jan Stojaspal explores the role of value-based pricing in gaining market access
Andrew Tolve explores how digital health coaching is helping the healthcare industry provide cost-effective services that boost adherence
Alex Gochtovtt, principal with Cognizant’s enterprise analytics practice, discusses pharma’s social media opportunities and the importance of data analytics
An interview with Serkan Erkovan of Boehringer Ingelheim.
Ashok Bhaseen, Vice President of Sales & Marketing at Pediapharm reveals how his company establishes trust when engaging KOLs